CoLucid – About the Company

CoLucid Pharmaceuticals (NasdaqGM: CLCD) is a clinical-stage biotechnology company that is developing lasmiditan to address an unmet medical need for acute migraine therapies. The Company is positioning the drug as a first-line therapy for individuals who are contraindicated from using triptans, the current standard-of-care, or as a second-line therapy for those who do not respond to triptans. CoLucid is currently evaluating lasmiditan in a Phase III trial under a Special Protocol Assessment (SPA) agreement with the FDA and expects to report results in the third quarter of 2016.